

UROPLASTY INC  
Form 10QSB  
February 11, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-QSB  
Quarterly Report Under section 13 or 15(d) of the Securities Exchange Act of 1934  
For the Quarterly Period Ended December 31, 2007  
Commission File No. 000-20989  
UROPLASTY, INC.  
(Name of Small Business Issuer in its Charter)**

**Minnesota, U.S.A.**  
(State or other jurisdiction of  
incorporation or organization)

**41-1719250**  
(I.R.S. Employer  
Identification No.)

**5420 Feltl Road  
Minnetonka, Minnesota, 55343**  
(Address of principal executive offices)

**(912) 426-6140**  
(Issuer's telephone number, including area code)

Securities registered under Section 12(g) of the Exchange Act: Common Stock, \$.01 par value (Title of class)  
Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definitions of "accelerated filer" and "large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer  Accelerated Filer  Non-accelerated Filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

YES  NO

The number of shares outstanding of the issuer's only class of common stock on January 31, 2008 was 14,916,540.

---

**TABLE OF CONTENTS**

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 3. CONTROLS AND PROCEDURES

PART II. OTHER INFORMATION

ITEM 6. EXHIBITS

SIGNATURES

Certification

Certification

---

**Table of Contents**PART I. FINANCIAL INFORMATION  
ITEM 1. FINANCIAL STATEMENTSUROPLASTY, INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS

	<b>December 31, 2007</b>	<b>March 31, 2007</b>
	<b>(unaudited)</b>	
Assets		
Current assets:		
Cash and cash equivalents	\$ 7,858,814	\$ 3,763,702
Short-term investments	2,448,447	3,000,000
Accounts receivable, net	1,837,827	1,240,141
Income tax receivable		113,304
Inventories	832,771	823,601
Other	207,364	272,035
Total current assets	13,185,223	9,212,783
Property, plant, and equipment, net	1,553,000	1,431,749
Intangible assets, net	4,426,101	308,093
Deferred tax assets	96,399	93,819
Total assets	\$ 19,260,723	\$ 11,046,444

See accompanying notes to the condensed consolidated financial statements.

**Table of Contents**

UROPLASTY, INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS

	<b>December 31, 2007 (unaudited)</b>	<b>March 31, 2007</b>
Liabilities and Shareholders' Equity		
Current liabilities:		
Current maturities - long-term debt	\$ 82,744	\$ 78,431
Deferred rent - current	35,000	35,000
Accounts payable	653,982	544,507
Accrued liabilities	1,705,592	1,347,670
Total current liabilities	2,477,318	2,005,608
Long-term debt - less current maturities	405,761	427,382
Deferred rent - less current portion	189,329	214,381
Accrued pension liability	346,838	596,026
Total liabilities	3,419,246	3,243,397
Shareholders' equity:		
Common stock \$.01 par value; 40,000,000 shares authorized, 14,916,540 and 11,614,330 shares issued and outstanding at December 31 and March 31, 2007, respectively	149,165	116,143
Additional paid-in capital	34,863,978	23,996,818
Accumulated deficit	(19,136,685)	(16,010,990)
Accumulated other comprehensive loss	(34,981)	(298,924)
Total shareholders' equity	15,841,477	7,803,047
Total liabilities and shareholders' equity	\$ 19,260,723	\$ 11,046,444

See accompanying notes to the condensed consolidated financial statements.

**Table of Contents**

UROPLASTY, INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(Unaudited)

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>December 31,</b>		<b>December 31,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
Net sales	\$ 3,729,314	\$ 2,158,273	\$ 9,717,531	\$ 5,683,253
Cost of goods sold	789,955	752,181	2,053,208	1,760,553
 Gross profit	 2,939,359	 1,406,092	 7,664,323	 3,922,700
 Operating expenses				
General and administrative	799,193	707,288	2,755,000	2,365,574
Research and development	460,374	424,987	1,393,496	1,758,350
Selling and marketing	2,399,227	1,301,575	6,006,598	3,837,858
Amortization of intangibles	209,862	25,210	632,865	78,323
	3,868,656	2,459,060	10,787,959	8,040,105
 Operating loss	 (929,297)	 (1,052,968)	 (3,123,636)	 (4,117,405)
 Other income (expense)				
Interest income	74,928	15,776	216,550	53,592
Interest expense	(6,497)	(8,671)	(27,141)	(25,136)
Warrant benefit		522,995		150,315
Foreign currency exchange gain (loss)	(37,632)	4,413	(53,538)	34,376
Other, net	2,134		4,014	3,585
	32,933	534,513	139,885	216,732
 Loss before income taxes	 (896,364)	 (518,455)	 (2,983,751)	 (3,900,673)
 Income tax expense	 4,004	 44,802	 141,944	 62,713
 Net loss	 \$ (900,368)	 \$ (563,257)	 \$ (3,125,695)	 \$ (3,963,386)
 Basic and diluted loss per common share	 \$ (0.06)	 \$ (0.07)	 \$ (0.23)	 \$ (0.51)
 Weighted average common shares outstanding:				
Basic and diluted	14,119,583	8,555,586	13,482,928	7,766,463

See accompanying notes to the condensed consolidated financial statements.

**Table of Contents**

UROPLASTY, INC. AND SUBSIDIARIES  
 CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY AND COMPREHENSIVE  
 LOSS  
 Nine months ended December 31, 2007  
 (Unaudited)

	Common Stock Shares	Common Stock Amount	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total Shareholders Equity
Balance (deficit) at March 31, 2007	11,614,330	\$ 116,143	\$ 23,996,818	\$ (16,010,990)	\$ (298,924)	\$ 7,803,047
Issuance of common stock in connection with the purchase of intellectual property	1,417,144	14,171	4,644,690			4,658,861
Proceeds from secondary offering, net of issuance costs of \$526,465	1,466,400	14,664	4,591,271			4,605,935
Registration costs private placement			(17,000)			(17,000)
Proceeds from exercise of warrants	50,000	500	149,500			150,000
Proceeds from exercise of stock options	368,666	3,687	631,611			635,298
Share-based consulting and compensation expense			867,088			867,088
Comprehensive loss				(3,125,695)	263,943	(2,861,752)
Balance(deficit) at December 31, 2007	14,916,540	\$ 149,165	\$ 34,863,978	\$ (19,136,685)	\$ (34,981)	\$ 15,841,477

See accompanying notes to the condensed consolidated financial statements.



**Table of Contents**

UROPLASTY, INC. AND SUBSIDIARIES  
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
 Nine Months Ended December 31, 2007 and 2006  
 (Unaudited)

	<b>Nine Months Ended December 31,</b>	
	<b>2007</b>	<b>2006</b>
Cash flows from operating activities:		
Net loss	\$ (3,125,695)	\$ (3,963,386)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	796,748	223,048
Gain on disposal of equipment	(2,769)	(3,576)
Warrant benefit		(150,315)
Stock-based consulting expense	37,942	48,043
Stock-based compensation expense	829,146	587,904
Deferred income taxes	7,113	(64,694)
Deferred rent	(26,250)	(23,333)
Changes in operating assets and liabilities:		
Accounts receivable	(534,542)	(365,812)
Inventories	64,390	(149,247)
Other current assets and income tax receivable	191,921	288,974
Accounts payable	94,198	91,619
Accrued liabilities and income tax payable	312,158	(24,069)
Accrued pension liability, net	(247,388)	214,909
Net cash used in operating activities	(1,603,028)	(3,289,935)
Cash flows from investing activities:		
Proceeds from sale of short-term investments	4,200,000	1,137,647
Purchase of short-term investments	(3,648,447)	
Purchases of property, plant and equipment	(210,875)	(150,578)
Proceeds from sale of equipment	4,811	4,294
Payments for intangible assets	(92,013)	
Net cash provided by investing activities	253,476	991,363
Cash flows from financing activities:		
Proceeds from financing obligations	178,374	210,999
Repayment of debt obligations	(239,872)	(158,820)
Net proceeds from issuance of common stock, warrants and option exercise	5,374,233	6,393,795
Net cash provided by financing activities	5,312,735	6,445,974
Effect of exchange rates on cash and cash equivalents	131,929	3,663

Edgar Filing: UROPLASTY INC - Form 10QSB

Net increase in cash and cash equivalents	4,095,112	4,151,065
Cash and cash equivalents at beginning of period	3,763,702	1,563,433
Cash and cash equivalents at end of period	\$ 7,858,814	\$ 5,714,498
Supplemental disclosure of cash flow information:		
Cash paid during the period for interest	\$ 25,204	\$ 22,011
Cash paid during the period for income taxes	87,900	93,935
Supplemental disclosure of non-cash financing and investing activities:		
Employee retirement savings plan contribution issued in common shares		44,385
Property, plant and equipment additions funded by lessor allowance and classified as deferred rent		280,000
Purchase of intellectual property funded by issuance of stock	4,658,861	
See accompanying notes to the condensed consolidated financial statements.		

Page 6

**Table of Contents**

**UROPLASTY, INC. AND SUBSIDIARIES**  
Notes to the Condensed Consolidated Financial Statements  
(Unaudited)

**1. Basis of Presentation**

We have prepared our condensed consolidated financial statements included in this Form 10-QSB, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to such rules and regulations. The consolidated results of operations for any interim period are not necessarily indicative of results for a full year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-KSB for the year ended March 31, 2007.

The condensed consolidated financial statements presented herein as of December 31, 2007 and for the three- and nine-month periods ended December 31, 2007 and 2006 reflect, in the opinion of management, all material adjustments consisting only of normal recurring adjustments necessary for a fair presentation of the consolidated financial position, results of operations and cash flows for the interim periods.

We have identified certain accounting policies that we consider particularly important for the portrayal of our results of operations and financial position and which may require the application of a higher level of judgment by our management, and as a result are subject to an inherent level of uncertainty. These are characterized as critical accounting policies and address revenue recognition, accounts receivable, inventories, foreign currency translation and transactions, impairment of long-lived assets, share-based compensation, defined benefit pension plans and income taxes, each of which is described in our Annual Report on Form 10-KSB for the year ended March 31, 2007. Based upon our review, we have determined that these policies remain our most critical accounting policies for the three- and nine-month periods ended December 31, 2007, and we have made no changes to these policies during fiscal 2008.

**2. Nature of Business, Sales of Common Stock and Corporate Liquidity**

**Overview**

We are a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent<sup>®</sup> PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder symptoms (OAB). We also offer Macroplastique<sup>®</sup> Implants, a bulking agent for the treatment of urinary incontinence. We believe that physicians prefer our products because they offer an effective therapy for the patient, can be administered in office-based settings and, with reimbursement in place, provide the physicians a new profitable recurring revenue stream. We believe that patients prefer our products because they are non-surgical treatment alternatives that do not have the side effects associated with pharmaceutical treatment options.

**Strategy**

Our goal is to become the leading provider of non-surgical neurostimulation solutions for patients who suffer from OAB symptoms. We also plan to market other innovative products to physicians focused on office-based procedures for the treatment of urinary incontinence. We believe that, with our Urgent PC and Macroplastique products, we will increasingly garner the attention of key physicians, independent sales representatives and distributors to grow revenue. The key elements of our strategy are to:

educate physicians about the benefits of our Urgent PC neurostimulation system;

build patient awareness of office-based solutions;

focus on office-based solutions for physicians;

increase market coverage in the United States and internationally; and

develop, license or acquire new products.



**Table of Contents****Our Products**

The Urgent PC neurostimulation system is a minimally invasive device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. The treatment can be administered by qualified office-based staff under the supervision of a physician. The system uses percutaneous tibial nerve stimulation to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function. We have received regulatory approvals for sale of the Urgent PC system in the United States, Canada and Europe. We launched sales of our second generation Urgent PC system in late 2006.

Macroplastique is a minimally invasive, implantable soft tissue bulking product for the treatment of urinary incontinence. When Macroplastique is injected into tissue around the urethra, it stabilizes and bulks tissues close to the urethra, thereby providing the surrounding muscles with increased capability to control the release of urine. Macroplastique has been sold for urological indications in over 40 countries outside the United States since 1991. In October 2006, we received from the FDA pre-market approval for the use of Macroplastique to treat female stress incontinence. We began marketing this product in the United States in early 2007.

**Sales and Marketing**

We are focusing our sales and marketing efforts primarily on office-based and outpatient surgery-based urologists, urogynecologists and gynecologists with significant patient volume. We believe the United States is a significant opportunity for future sales of our products. In order to grow our United States business, we have expanded our sales organization, consisting of direct field sales and independent sales representatives, marketing organization and reimbursement department to market our products directly to our customers. By expanding our United States presence, we intend to develop long-standing relationships with leading physicians treating overactive bladder symptoms and incontinence.

**Sales of Common Stock and Corporate Liquidity**

Our future liquidity and capital requirements will depend on numerous factors including: acceptance of our products, and the timing and cost involved in manufacturing scale-up and in expanding our sales, marketing and distribution capabilities, in the United States markets; the cost and effectiveness of our marketing and sales efforts with respect to our existing products in international markets; the effect of competing technologies and market and regulatory developments; and the cost involved in protecting our proprietary rights.

We believe we have sufficient liquidity to meet our needs over the next twelve months. However, we may need to raise additional financing to support our operations and planned growth activities in the future as we have yet to achieve profitability and generate positive cash flows. To achieve profitability, we must generate substantially more revenue than we have this year or in prior years. Our ability to achieve significant revenue growth will depend, in large part, on our ability to achieve widespread market acceptance for our products and successfully expand our business in the U.S., which we cannot guarantee will happen. There can be no guarantee that we will be successful at raising additional equity or debt financing, as we currently have no committed sources.

In November 2007, we conducted a follow-on public offering in which we sold 1,466,400 shares of our common stock at a price per share of \$3.50, for an aggregate purchase price of approximately \$5.1 million. The stock sale proceeds are offset by costs of approximately \$526,000, resulting in net proceeds of approximately \$4.6 million.

**3. Short-term Investments**

At December 31, 2007, short-term investments consisted of \$2,448,447 of certificates of deposit maturing in the fourth quarter of fiscal 2008.

**4. Inventories**

Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). The reserve for slow moving and obsolete inventories was \$59,000 and \$229,000 at December 31, 2007 and March 31, 2007, respectively. Inventories, net of reserve, consist of the following:

	<b>December 31, 2007</b>	<b>March 31, 2007</b>
Raw materials	\$ 273,263	\$ 254,988
Work-in-process	15,298	20,773
Finished goods	544,210	547,840

\$ 832,771 \$ 823,601

**Table of Contents****5. Intangible Assets**

Intangible assets are comprised of patents, trademarks and licensed technology which are amortized on a straight-line basis over their estimated useful lives or contractual terms, whichever is less. In April 2007, we acquired from CystoMedix, Inc. certain intellectual property assets related to the Urgent PC system, which was previously licensed to us. In consideration, we issued CystoMedix 1,417,144 shares of our common stock. We have capitalized \$4.7 million of the acquisition costs as patents and inventions.

The following is a summary of intangible assets at December 31, 2007 and March 31, 2007:

	Estimated Useful Lives (Years)	December 31, 2007		
		Gross Carrying Amount	Accumulated Amortization	Net value
Licensed technology	5	\$ 26,290	\$ 26,290	\$
Patents and inventions	6	5,463,774	1,037,673	4,426,101
<b>Totals</b>		\$ 5,490,064	\$ 1,063,963	\$ 4,426,101

		March 31, 2007		
		Gross Carrying Amount	Accumulated Amortization	Net value
Licensed technology	5	\$ 26,290	\$ 26,290	\$
Patents and inventions	6	712,900	404,807	308,093
<b>Totals</b>		\$ 739,190	\$ 431,097	\$ 308,093

Estimated annual amortization for these assets for the fiscal years ended March 31 is as follows:

Remainder of fiscal 2008	\$ 211,564
2009	846,152
2010	843,869
2011	840,899
2012	840,500
Thereafter	843,117
	\$ 4,426,101

**6. Deferred Rent and Leasehold Improvements**

We entered into an 8-year operating lease agreement, effective May 2006, for our corporate facility. As part of the agreement, the landlord provided an incentive of \$280,000 for leasehold improvements. We recorded this incentive as deferred rent and are amortizing it as a reduction in lease expense over the lease term in accordance to SFAS 13,

Accounting for Leases and FASB Technical Bulletin 88-1, Issues Relating to Accounting for Leases. We are amortizing the leasehold improvements over the shorter of the asset life or the lease term.

**Table of Contents****7. Comprehensive Loss**

Comprehensive loss consists of net loss, translation adjustments and additional pension liability as follows:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>December 31,</b>		<b>December 31,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
Net loss	\$ (900,368)	\$ (563,257)	\$ (3,125,695)	\$ (3,963,386)
Items of other comprehensive income (loss):				
Translation adjustment	97,349	77,297	276,378	155,394
Pension related	(771)	(8,792)	(12,435)	(20,611)
Comprehensive loss	\$ (803,790)	\$ (494,752)	\$ (2,861,752)	\$ (3,828,603)

**8. Net Loss per Common Share**

The following options and warrants outstanding at December 31, 2007 and 2006, to purchase shares of common stock, were excluded from diluted loss per common share because of their anti-dilutive effect:

	<b>Number of</b>	<b>Range of Exercise</b>
	<b>Options/Warrants</b>	<b>Prices</b>
For the nine months ended:		
December 31, 2007	4,147,528	\$1.82 to \$5.30
December 31, 2006	4,953,679	\$1.10 to \$5.30

**9. Warrants**

As of December 31, 2007, we had issued and outstanding warrants to purchase an aggregate of 2,116,928 common shares, at a weighted average exercise price of \$3.81.

In connection with our private equity offerings in April 2005 and August 2006 and our December 2006 follow-on public offering, we issued five-year warrants to purchase 1,180,928, 764,500 and 121,500 common shares, respectively, at exercise prices of \$4.75, \$2.50 and \$2.40 per share, respectively.

As part of a consulting agreement, we have outstanding five-year warrants, issued in November 2003 to CCRI Corporation, to purchase 50,000 shares of common stock at a per share price of \$5.00.

Proceeds from the exercise of warrants were \$150,000 for the nine months ended December 31, 2007.

**10. Share-based Compensation**

As of December 31, 2007, we had one active plan (2006 Stock and Incentive Plan) for share-based compensation grants. Under the plan, if we have a change in control, all outstanding grants, including those subject to vesting or other performance targets, fully vest immediately. Under this plan, we had reserved 1,200,000 shares of our common stock for stock-based grants, and as of December 31, 2007, we had remaining 532,000 shares available for grant. We generally grant option awards with an exercise price equal to the closing market price of our stock at the date of the grant.

We account for share-based compensation costs under Statement of Financial Accounting Standards No. 123(R),

Share-Based Payment Revised 2004. We incurred a total of approximately \$829,000 and \$588,000 in share-based compensation expense for the nine months ended December 31, 2007 and 2006, respectively.

Proceeds from the exercise of stock options were \$635,000 for the nine months ended December 31, 2007.



**Table of Contents**

We determined the fair value of our option awards using the Black-Scholes option pricing model. We used the following weighted-average assumptions to value the options granted during the following periods:

	<b>Nine Months Ended December 31, 2007</b>	<b>Nine Months Ended December 31, 2006</b>
Expected life in years	4.08	7.40
Risk-free interest rate	4.57%	4.96%
Expected volatility	91.88%	100.26%
Expected dividend yield	0	0
Weighted-average fair value	\$ 2.84	\$ 1.95

The expected life selected for options granted during the quarter represents the period of time that we expect our options to be outstanding based on historical data of option holder exercise and termination behavior for similar grants. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate over the expected life at the time of grant. Expected volatilities are based upon historical volatility of our stock. We estimate a forfeiture rate for stock awards of up to 10.9% in 2008 based on the historical employee turnover rates. The expected life of the options is based on the historical life of previously granted options, which are generally held to maturity.

As of December 31, 2007, we had approximately \$701,000 of unrecognized compensation cost related to share-based payments that we expect to recognize over a weighted-average period of 1.41 years.

The following table summarizes the activity related to our stock options during the nine months ended December 31, 2007:

	<b>Number of Shares</b>	<b>Weighted Avg. Exercise Price</b>	<b>Weighted Avg. Remaining Contractual Life (Years)</b>	<b>Aggregate Intrinsic Value</b>
Options outstanding at beginning of period	2,169,866	\$ 3.62		
Options granted	312,500	4.23		
Options exercised	(368,666)	1.72		
Options surrendered	(83,100)	4.66		
Options outstanding at end of period	2,030,600	\$ 4.01	5.11	\$ 1,349,450
Exercisable at end of period	1,571,596	\$ 4.25	5.04	\$ 852,732

**11. Savings and Retirement Plans**

We sponsor various plans for eligible employees in the United States, the United Kingdom (UK), and The Netherlands. Our retirement savings plan in the United States conforms to Section 401(k) of the Internal Revenue Code and participation is available to substantially all employees. We made no discretionary contributions in association with these plans in the United States for the three- and nine-month periods ended December 31, 2007. For

the nine months ended December 31, 2006, we made a contribution of \$44,408, substantially all of which was in the form of our fully vested common stock.

Our international subsidiaries have defined benefit retirement plans for eligible employees. These plans provide benefits based on the employee's years of service and compensation during the years immediately preceding retirement, termination, disability, or death, as defined in the plans. We froze the UK subsidiary's defined benefit plan on December 31, 2004 and established a defined contribution plan on March 10, 2005. Effective April 1, 2005, we closed The Netherlands subsidiary's defined benefit retirement plan for new participants and established a defined contribution plan for new employees.

**Table of Contents**

The cost for our defined benefit retirement plans in The Netherlands and the United Kingdom includes the following components for the three and nine-months ended December 31, 2007 and 2006:

	<b>Three Months Ended December 31,</b>		<b>Nine Months Ended December 31,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
Gross service cost	\$ 22,841	\$ 51,882	\$ 65,768	\$ 153,727
Interest cost	23,837	31,355	69,232	92,710
Expected return on assets	(17,560)	(18,017)	(51,029)	(53,224)
Amortization	1,646	10,737	4,856	31,772
Net periodic retirement cost	\$ 30,764	\$ 75,957	\$ 88,827	\$ 224,985

Major assumptions used in the above calculations include:

	<b>Nine Months Ended December 31,</b>	
	<b>2007</b>	<b>2006</b>
Discount rate	4.90-5.30%	4.25-5.50%
Expected return on assets	4.90-5.00%	4.00-5.00%
Expected rate of increase in future compensation:		
General	3%	3%
Individual	0%-3%	0%-3%

We made contributions of approximately \$381,000 and \$6,000, respectively, during the nine-month periods ended December 31, 2007 and 2006 to The Netherlands and to the United Kingdom defined benefit pension plans. For the remainder of the fiscal year we expect to make approximately \$10,000 in additional contributions for the two plans.

**12. Foreign Currency Translation**

We translate all assets and liabilities using period-end exchange rates. We translate statements of operations items using average exchange rates for the period. We record the resulting translation adjustment within accumulated other comprehensive loss, a separate component of shareholders' equity. We recognize foreign currency transaction gains and losses in our consolidated statements of operations, including unrealized gains and losses on short-term intercompany obligations using period-end exchange rates. We recognize unrealized gains and losses on long-term intercompany obligations within accumulated other comprehensive loss, a separate component of shareholders' equity. We recognize exchange gains and losses primarily as a result of fluctuations in currency rates between the U.S. dollar (the functional reporting currency) and the Euro and British pound (currencies of our subsidiaries), as well as their effect on the dollar denominated intercompany obligations between us and our foreign subsidiaries. All intercompany balances are revolving in nature and we do not deem them to be long-term balances. For the three months ended December 31, 2007 and 2006, we recognized foreign currency (loss) gain of \$(37,600) and \$4,400, respectively. For the nine months ended December 31, 2007 and 2006, we recognized foreign currency (loss) gain of \$(53,500) and \$34,400, respectively.

**13. Income Tax Expense**

During the three months ended December 31, 2007 and 2006, our Dutch subsidiaries recorded income tax expense of \$3,000 and \$44,800, respectively. During the nine months ended December 31, 2007 and 2006, our Dutch subsidiaries recorded income tax expense of \$140,600 and \$62,700, respectively. During the three months ended December 31, 2007 and 2006, our U.S. organization recorded income tax expense of \$1,000 and \$0, respectively. During the nine months ended December 31, 2007 and 2006, our U.S. organization recorded income tax expense of \$1,300 and \$0, respectively. We cannot use our



**Table of Contents**

U.S. net operating loss carry forwards to offset taxable income in foreign jurisdictions. Effective January 1, 2007, the maximum Dutch income tax rate is 25.5% for taxable income in excess of 60,000.

Effective April 1, 2007, we adopted FASB Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes an Interpretation of FASB Statement 109, which prescribes a recognition threshold and a measurement attribute for financial statement recognition of tax positions taken or expected to be taken in a tax return. It is management's responsibility to determine whether it is more-likely than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. At adoption on April 1, 2007, we had no unrecognized tax benefits which needed adjustment. We reviewed all income tax positions taken or that we expect to be taken for all open tax years and determined that our income tax positions are appropriately stated and supported for all open years and that the adoption of FIN 48 did not have a significant effect on our consolidated financial statements.

Under our accounting policies we would recognize interest and penalties accrued on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At the adoption date of April 1, 2007, we recognized no interest or penalties related to uncertain tax positions. As of December 31, 2007, we recorded no accrued interest or penalties related to uncertain tax positions.

The fiscal tax years 2004 through 2007 remain open to examination by the Internal Revenue Service and various state taxing jurisdictions to which we are subject. In addition, we are subject to examination by certain foreign taxing authorities for which the fiscal years 2005 through 2007 remain open for examination.

We expect no significant change in the amount of unrecognized tax benefit, accrued interest or penalties within the next 12 months.

**14. Geographic Information**

We are a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder symptoms (OAB). We also offer Macroplastique, a bulking agent for the treatment of urinary incontinence. Based upon the above, we operate in only one reportable segment consisting of medical products, primarily for the voiding dysfunctions market served primarily by urologists, urogynecologists and gynecologists.

**Table of Contents**

Information regarding operations in different geographies for the three months ended December 31, 2007 and 2006 is as follows:

	<b>United States</b>	<b>The Netherlands</b>	<b>United Kingdom</b>	<b>Eliminations *</b>	<b>Consolidated</b>
<b>Fiscal 2008</b>					
Sales, three months ended December 31, 2007	\$2,636,412	\$1,351,179	\$697,757	\$(956,034)	\$3,729,314
Income tax expense, three months ended December 31, 2007	1,000	3,004			4,004
Net income (loss), three months ended December 31, 2007	(755,496)	4,001	(80,637)	(68,236)	(900,368)
Long-lived assets At December 31, 2007	5,185,339	788,816	4,947		5,979,101
<b>Fiscal 2007</b>					
Sales, three months ended December 31, 2006	\$ 737,391	\$1,586,040	\$531,876	\$(697,034)	\$2,158,273
Income tax expense, three months ended December 31, 2006		44,802			44,802
Net income (loss), three months ended December 31, 2006	(796,316)	145,649	128,873	(41,463)	(563,257)
Long-lived assets At December 31, 2006	1,007,348	749,890	5,242		1,762,480

Information regarding operations in different geographies for the nine months ended December 31, 2007 and 2006 is as follows:

	<b>United States</b>	<b>The Netherlands</b>	<b>United Kingdom</b>	<b>Eliminations *</b>	<b>Consolidated</b>
<b>Fiscal 2008</b>					
Sales, nine months ended December 31, 2007	\$ 5,840,807	\$4,569,333	\$1,861,670	\$(2,554,279)	\$ 9,717,531
Income tax expense, nine months ended	1,300	140,644			141,944

December 31, 2007

Net income (loss), nine months ended December 31, 2007	(3,241,509)	389,828	(233,776)	(40,238)	(3,125,695)
--	-------------	---------	-----------	----------	-------------

**Fiscal 2007**

Sales, nine months ended December 31, 2006	\$ 1,743,424	\$4,001,621	\$1,484,583	\$(1,546,375)	\$ 5,683,253
--	--------------	-------------	-------------	---------------	--------------

Income tax expense, nine months ended December 31, 2006		62,713			62,713
---	--	--------	--	--	--------

Net income (loss), nine months ended December 31, 2006	(4,151,691)	254,859	29,530	(96,084)	(3,963,386)
--	-------------	---------	--------	----------	-------------

\* The information in the column entitled Eliminations represents intercompany transactions.

**Table of Contents**

**15. Recently Issued Accounting Standards**

In September 2006, the Financial Accounting Standards Board, or FASB, issued SFAS No. 157, Fair Value Measurements (SFAS No. 157). SFAS No. 157 establishes a common definition for fair value to be applied to US GAAP guidance requiring use of fair value, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007. We are currently assessing the impact of SFAS No. 157 but do not believe the adoption will have a significant impact on our financial position and results of operations.

On February 15, 2007, the FASB, issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities. Under SFAS No. 159, we may elect to report financial instruments and certain other items at fair value on a contract-by-contract basis with changes in value reported in earnings. This election is irrevocable. SFAS No. 159 provides an opportunity to mitigate volatility in reported earnings caused by measuring hedged assets and liabilities that were previously required to use a different accounting method than the related hedging contracts when the complex hedge accounting provisions of SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, are not met. SFAS No. 159 is effective for years beginning after November 15, 2007. If we adopt this standard, we do not expect it to have a material effect on our financial statements.



**Table of Contents**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

We recommend that you read this Report on Form 10-QSB in conjunction with our Annual Report on Form 10-KSB for the year ended March 31, 2007.

**Forward-looking Statements**

We may from time to time make written or oral forward-looking statements, including our statements contained in this filing with the Securities and Exchange Commission and in our reports to stockholders, as well as elsewhere.

Forward-looking statements are statements such as those contained in projections, plans, objectives, estimates, statements of future economic performance, and assumptions related to any of the foregoing, and may be identified by the use of forward-looking terminology, such as may, expect, anticipate, estimate, goal, continue, or other comparable terminology. By their very nature, forward-looking statements are subject to known and unknown risks and uncertainties relating to our future performance that may cause our actual results, performance, or achievements, or industry results, to differ materially from those expressed or implied in any such forward-looking statements. Any such statement is qualified by reference to the following cautionary statements.

Our business operates in highly competitive markets and is subject to changes in general economic conditions, competition, customer and market preferences, government regulation, the impact of tax regulation, foreign exchange rate fluctuations, the degree of market acceptance of products, the uncertainties of potential litigation, as well as other risks and uncertainties detailed elsewhere herein and from time to time in our Securities and Exchange Commission filings.

In this filing, the section entitled Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements. Various factors and risks (not all of which are identifiable at this time) could cause our results, performance, or achievements to differ materially from that contained in our forward-looking statements, and investors are cautioned that any forward-looking statement contained herein or elsewhere is qualified by and subject to the warnings and cautionary statements contained above and in our other filings with the Securities and Exchange Commission.

We do not undertake, nor assume obligation, to update any forward-looking statement that we may make from time to time.

**Overview**

We are a medical device company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder (OAB) symptoms. We also offer Macroplastique, a bulking agent for the treatment of urinary incontinence. We believe that physicians prefer our products because they offer an effective therapy for the patient, can be administered in office-based settings and, with reimbursement in place, provide the physicians a new profitable recurring revenue stream. We believe that patients prefer our products because they are non-surgical treatment alternatives that do not have the side effects associated with pharmaceutical treatment options.

The Urgent PC neurostimulation system is a minimally invasive device designed for office-based treatment of OAB symptoms of urge incontinence, urinary urgency and urinary frequency. The treatment can be administered by qualified office-based staff under the supervision of a physician. The Urgent PC system uses percutaneous tibial nerve stimulation to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function. We have received regulatory approvals for sale of the Urgent PC system in the United States, Canada and Europe. We launched sales of our second generation Urgent PC system in late 2006.

Macroplastique is a minimally invasive, implantable soft tissue bulking agent for the treatment of urinary incontinence. When Macroplastique is injected into tissue around the urethra, it stabilizes and bulks tissues close to the urethra, thereby providing the surrounding muscles with increased capability to control the release of urine.

Macroplastique has been sold for urological indications in over 40 countries outside the United States since 1991. In October 2006, we received from the FDA pre-market approval for the use of Macroplastique to treat female stress incontinence. We began marketing Macroplastique in the United States in early 2007.

We are focusing our sales and marketing efforts primarily on urologists, urogynecologists and gynecologists with significant office-based and outpatient surgery-based patient volume. We believe the United States is a significant opportunity for future

**Table of Contents**

sales of our products. In order to grow our United States business, we recently established a sales organization, consisting of direct field sales personnel and independent sales representatives, and a marketing organization to market our products directly to our customers. By expanding our United States presence, we intend to develop long-standing relationships with leading physicians treating OAB symptoms and incontinence.

**Critical Accounting Policies**

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the U.S., which require us to make estimates and assumptions in certain circumstances that affect amounts reported. In preparing these consolidated financial statements, we have made our best estimates and judgments of certain amounts, giving due consideration to materiality. We believe that of our significant accounting policies, the following are particularly important to the portrayal of our results of operations and financial position. They may require the application of a higher level of judgment by Uroplasty management, and as a result are subject to an inherent degree of uncertainty.

*Revenue Recognition.* The Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 104, Revenue Recognition in Financial Statements, provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues. We believe our revenue recognition policies comply with SAB 104. We recognize revenue upon shipment of product to our distributors and direct customers. We have no customer acceptance provisions or installation obligations. Our sales terms to our distributors and customers provide no right of return outside of our standard warranty, and payment terms consistent with industry standards apply. Sales terms and pricing to our distributors are governed by the respective distribution agreements. Our distributors purchase our products to meet the sales demand of their end-user customers as well as to fulfill their internal requirements associated with the sales process and, if applicable, contractual purchase requirements under the respective distribution agreements. Internal and other requirements include purchases of products for training, demonstration and evaluation purposes, clinical evaluations, product support, establishing inventories, and meeting minimum purchase commitments. As a result, the level of our net sales during any period is not necessarily indicative of our distributors sales to end-user customers during that period, which we estimate were not substantially different than our sales to those distributors in each of the three- and nine-month periods ended December 31, 2007 and 2006. Our distributors level of inventories of our products, their sales to end-user customers and their internal product requirements may impact our future revenue growth.

*Accounts Receivable.* We carry our accounts receivable at the original invoice amount less an estimate made for doubtful receivables based on a periodic review of all outstanding amounts. We determine the allowance for doubtful accounts based on customer financial health, and both historical and expected credit loss experience. We write off our accounts receivable when we deem them uncollectible. We record recoveries of accounts receivable previously written off when received.

*Inventories.* We state inventories at the lower of cost or market using the first-in, first-out method. We provide lower of cost or market reserves for slow moving and obsolete inventories based upon current and expected future product sales and the expected impact of product transitions or modifications. While we expect our sales to grow, a reduction in sales could reduce the demand for our products and may require additional inventory reserves.

*Foreign Currency Translation/Transactions.* We translate the financial statements of our foreign subsidiaries in accordance with the provisions of SFAS No. 52 Foreign Currency Translation. Under this Statement, we translate all assets and liabilities using period-end exchange rates, and we translate statements of operations items using average exchange rates for the period. We record the resulting translation adjustment within accumulated other comprehensive loss, a separate component of shareholders' equity. We recognize foreign currency transaction gains and losses in the statement of operations, including unrealized gains and losses on short-term intercompany obligations using period-end exchange rates, resulting in an increase in the volatility of our consolidated statements of operations. We recognize unrealized gains and losses on long-term intercompany obligations within accumulated other comprehensive loss, a component of comprehensive loss reflected as a separate item in shareholders' equity.

*Impairment of Long-Lived Assets.* Long-lived assets at December 31, 2007 consist of property, plant and equipment and intangible assets. We review our long-lived assets for impairment whenever events or business circumstances indicate that the carrying amount of an asset may not be recoverable. We measure the recoverability of assets to be

held and used by a comparison of the carrying amount of assets to future undiscounted net cash flows expected to be generated by the asset. If we consider such assets impaired, we measure the impairment to be recognized by the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value, less costs to sell.

**Table of Contents**

*Share-Based Compensation.* FASB published Statement No. 123 (revised 2004), *Share-Based Payment*, or SFAS 123(R). SFAS 123(R) requires that we recognize the compensation cost relating to share-based payment transactions, including grants of employee stock options, in our financial statements. We measure that cost based on the fair value of the equity or liability instruments issued. SFAS 123(R) covers a wide range of share-based compensation arrangements including stock options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans.

This Statement requires us to measure the cost of employee services received in exchange for stock options based on the grant-date fair value of the award, and to recognize the cost over the period we require our employee to provide services for the award.

*Defined Benefit Pension Plans.* We have a liability attributed to defined benefit pension plans we offered to certain former and current employees prior to April 2005. We pay premiums to an insurance company to fund annuities and are responsible for funding additional annuities based on continued service and future salary increases for these employees' pension benefit. The liability is dependent upon numerous factors, assumptions and estimates, and the continued benefit costs we incur may be significantly affected by changes in key actuarial assumptions such as the discount rate, compensation rates, or retirement dates used to determine the projected benefit obligation. Additionally, changes made to the provisions of the plans may impact current and future benefit costs. In accordance with accounting rules, we may not immediately recognize changes in benefit obligations associated with these factors as costs on the income statement, but may recognize them in future years over the remaining average service period of plan participants.

*Income Taxes.* We recognize deferred tax assets and liabilities for future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using enacted tax rates we expect to apply to taxable income in the years in which we expect to recover or settle those temporary differences. As of March 31, 2007, we have generated approximately \$18 million in U.S. net operating loss carryforwards that we cannot use to offset taxable income in foreign jurisdictions. We recognize a valuation allowance when we determine it is more likely than not that we will not realize all or a portion of the deferred tax asset. We have established a valuation allowance for all U.S. and certain foreign deferred tax assets due to the uncertainty that we will generate enough income in those taxing jurisdictions to utilize the assets. In addition, future utilization of NOL carryforwards is subject to certain limitations under Section 382 of the Internal Revenue Code. This section generally relates to a 50 percent change in ownership of a company over a three-year period. We believe that the issuance of our common stock in the December 2006 and November 2007 follow-on public offerings resulted in an ownership change under Section 382. Accordingly, our ability to use NOL tax attributes generated prior to these offerings will likely be limited.

Set forth below is management's discussion and analysis of the financial condition and results of operations for the three and nine-months ended December 31, 2007 and 2006. See Note 14 to our condensed consolidated financial statements for geographic information.

**Results of Operations****Three months ended December 31, 2007 compared to three months ended December 31, 2006**

*Net Sales:* During the three months ended December 31, 2007, net sales of \$3.7 million represented a \$1.6 million, or a 73% increase, over net sales of \$2.2 million for the three months ended December 31, 2006. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales increased by approximately 65%. We attribute this growth in sales to our customers in the U.S. as a result of our expanded U.S. sales organization and the continued growth in sales of our Urgent PC system.

Sales to customers in the U.S. in the three months ended December 31, 2007 increased to \$2.0 million from \$396,000 in the three months ended December 31, 2006. Sales for the three months ended December 31, 2007, represent a sequential, quarter-to-quarter increase from \$1.2 million in the previous quarter. We attribute this growth primarily to the Urgent PC system and the expanded sales organization. During the three months ended December 31, 2007, we had minimal sales of our Macroplastique product in the U.S., which we launched in the U.S. early in 2007.

Sales to customers outside the U.S. for the three months ended December 31, 2007 and 2006 were \$1.8 million in each period. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales declined by

approximately 10%. We attribute the decline primarily to the decline in sales of our Macroplastique-related products.

**Table of Contents**

**Gross Profit:** Gross profit was \$2.9 million and \$1.4 million for the three months ended December 31, 2007 and 2006, respectively, or 79% and 65% of net sales in the respective periods. In the three months ended December 31, 2006 we incurred \$107,000 of charges related to rework, scrap and warranty for one of our new products and an estimated \$60,000 of costs related to underutilization of the manufacturing facility as we shifted production to the earlier quarter to accommodate the manufacturing transition to the new facility and charges for duplicate facilities in the U.S. We attribute the higher gross profit percentage in the three months ended December 31, 2007, to the increase in manufacturing capacity utilization, savings of approximately \$99,000 (offset by \$122,000 of rent and lease exit charges) due to the discontinuation of manufacturing at our Eindhoven, The Netherlands facility. We also realized a favorable impact of approximately two percentage points in gross margin during the 2007 period due to an increase in the average selling price in the U.S. of the lead sets used with our Urgent PC system and a favorable product mix. We estimate that, during the 2007 period, increased manufacturing capacity utilization, as a result of increased sales, added approximately five to six percentage points to our gross margin.

**General and Administrative Expenses (G&A):** G&A expenses increased from \$707,000 during the three months ended December 31, 2006 to \$799,000 during the same period in 2007. Included in the three-month period ended December 31, 2006 is a \$127,000 non-cash, SFAS 123 (R) charge for share-based employee compensation, compared with a charge of \$101,000 in the three-month period ended December 31, 2007. Excluding share-based compensation charges, G&A expenses increased by \$118,000, primarily because of an increase in personnel-related costs and consulting fees primarily related to Sarbanes-Oxley compliance.

**Research and Development Expenses (R&D):** R&D expenses increased from \$425,000 during the three months ended December 31, 2006 to \$460,000 during the same period in 2007. We attribute the increase primarily to increase in spending of \$105,000 for clinical studies, partially offset by a decrease in personnel-related costs of \$44,000.

**Selling and Marketing Expenses (S&M):** S&M expenses increased from \$1.3 million during the three months ended December 31, 2006 to \$2.4 million during the same period in 2007. We attribute the increase to a \$742,000 increase primarily for commissions to independent sales representatives and compensation-related costs for our expanded sales organization, an \$92,000 charge related to severance expense, a \$50,000 increase in costs to attend tradeshow, an \$133,000 increase in travel related costs, and an increase in other costs to support our expanded sales organization and marketing activities.

**Amortization of Intangibles:** Amortization of intangibles increased from \$25,000 during the three months ended December 31, 2006 to \$210,000 during the same period in 2007. In April 2007, we acquired from CystoMedix, Inc., certain intellectual property assets related to the Urgent PC system for \$4.7 million. We began amortizing the intellectual property assets acquired over six years starting in April 2007.

**Other Income (Expense):** Other income (expense) includes interest income, interest expense, warrant expense, foreign currency exchange gains and losses and other non-operating costs when incurred. Other income was \$33,000 and \$535,000 for the three months ended December 31, 2007 and 2006, respectively, with \$523,000 of the change resulting from a warrant benefit in the three months ended December 31, 2006.

In May 2002, we conducted a public rights offering. In the rights offering, we issued to those shareholders who exercised their rights three shares of our common stock and a warrant, exercisable through July 2004, to purchase an additional share of our common stock. We registered with the SEC the issuance of the shares, the warrants and the shares underlying the warrants. In July 2004, we suspended the right to exercise the warrants shortly before their scheduled expiration date because we announced a planned restatement of our fiscal 2004 financial statements. In November 2004, we became current with our SEC filings. In April 2005, we chose to issue like-kind replacement warrants to the holders of the expired warrants. The terms for the replacement warrants required that we issue shares covered by a registration statement and maintain the effectiveness of the registration (by making timely SEC filings) for the warrant holders to receive registered shares upon exercise of the warrants. In April 2005, we recognized a liability and equity charge of \$1.4 million associated with the grant of these warrants, and subsequently recognized in other income (expense) the change in fair value of the warrants due to the change in the value of our common stock issuable upon exercise of these warrants. We determined the fair value of the warrants using the Black-Scholes option-pricing model. The period to exercise the warrants ended in March 2007. We recognized a net warrant benefit of \$523,000 in the quarter ended December 31, 2006.

We recognize exchange gains and losses primarily as a result of fluctuations in currency rates between the U.S. dollar (the functional reporting currency) and the Euro and British pound (currencies of our subsidiaries), as well as their effect on the dollar denominated short-term intercompany obligations between us and our foreign subsidiaries. We recognized foreign currency (loss) gain of \$(37,600) and \$4,400 for the three months ended December 31, 2007 and 2006, respectively.



**Table of Contents**

**Income Tax Expense:** During the three months ended December 31, 2007 and 2006, our Dutch subsidiaries recorded income tax expense of \$3,000 and \$44,800, respectively. During the three months ended December 31, 2007 and 2006, our U.S. organization recorded income tax expense of \$1,000 and \$0, respectively. We cannot use our U.S. net operating loss carry forwards to offset taxable income in foreign jurisdictions. Effective January 1, 2007, the maximum Dutch income tax rate is 25.5% for taxable income in excess of 60,000.

**Nine months ended December 31, 2007 compared to nine months ended December 31, 2006**

**Net Sales:** During the nine months ended December 31, 2007, net sales of \$9.7 million represented a 71% increase, over net sales of \$5.7 million for the nine months ended December 31, 2006. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales increased by approximately 64%. We attribute this growth primarily to an increase in sales to our customers in the U.S. as a result of our expanded U.S. sales organization, and the continued growth in sales of our Urgent PC system.

Sales to customers in the U.S. increased to \$4.2 million during the nine months ended December 31, 2007, from \$752,000 in the same period last year. We attribute this growth primarily to the Urgent PC system and the expanded sales organization. During the nine months ended December 31, 2007, we had minimal sales of our Macroplastique product in the U.S., which we launched in the U.S. early in 2007, and the I-Stop product, which we discontinued.

Sales to customers outside the U.S. for the nine months ended December 31, 2007 were \$5.5 million, representing a 12% increase, compared to \$4.9 million for the nine months ended December 31, 2006. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales increased by approximately 4%. We attribute the increase primarily to the increase in sales of our Macroplastique-related products.

**Gross Profit:** Gross profit was \$7.7 million and \$3.9 million for the nine months ended December 31, 2007 and 2006, respectively, or 79% and 69% of net sales in the respective periods. We attribute the lower gross profit percentage for the nine months ended December 31, 2006 primarily to the \$107,000 of charges related to rework, scrap and warranty for one of our new products and an estimated \$72,000 of costs associated duplicate manufacturing facilities in the U.S.

We attribute the higher gross profit percentage for the nine months ended December 31, 2007 to the increase in manufacturing capacity utilization, and savings of approximately \$260,000 (offset by \$122,000 of rent and lease exit charges) due to the discontinuation of manufacturing at our Eindhoven, The Netherlands facility. During the 2007 period, we also realized a favorable impact of approximately one percentage point in gross margin due to an increase in the average selling price in the U.S. of the lead sets used with our Urgent PC system and a favorable product mix. We estimate that, during the 2007 period, the increased manufacturing capacity utilization, as a result of increased sales, added approximately five percentage points to our gross margin.

**General and Administrative Expenses (G&A):** G&A expenses increased from \$2.4 million during the nine months ended December 31, 2006 to \$2.8 million during the same period in 2007. Included in the nine-month period ended December 31, 2006 is a \$519,000 non-cash, SFAS 123 (R) charge for share-based employee compensation, compared with a charge of \$565,000 in the nine-month period ended December 31, 2007. Excluding share-based compensation charges, G&A expenses increased by \$344,000, primarily because of an increase in personnel-related costs and consulting fees, offset by a reduction in rent expense for our leased facilities in the United Kingdom and the U.S.

**Research and Development Expenses (R&D):** R&D expenses decreased from \$1.8 million during the nine months ended December 31, 2006 to \$1.4 during the same period in 2007. We attribute the decrease primarily to reduced consulting expense of \$245,000 and a decrease in personnel-related costs of \$175,000. During the nine months ended December 31, 2006, we incurred consulting expense associated with the development of our second generation Urgent PC system and preparation for a clinical study.

**Selling and Marketing Expenses (S&M):** S&M expenses increased from \$3.8 million during the nine months ended December 31, 2006 to \$6.0 million during the same period in 2007. We attribute the increase primarily to a \$1.5 million increase in commissions for independent sales representatives and compensation-related costs for our expanded sales organization, an \$92,000 charge related to severance expense, a \$131,000 increase in costs to attend tradeshows, a \$201,000 increase in travel related costs, and an increase in other costs to support our expanded sales organization and marketing activities.

**Amortization of Intangibles:** Amortization of intangibles increased from \$78,000 during the nine months ended December 31, 2006 to \$633,000 during the same period in 2007. In April 2007, we acquired from CystoMedix, Inc.,

certain intellectual

**Table of Contents**

property assets related to the Urgent PC system for \$4.7 million. We began amortizing the intellectual property assets acquired over six years starting in April 2007.

Other Income (Expense): Other income (expense) includes interest income, interest expense, warrant expense, foreign currency exchange gains and losses and other non-operating costs when incurred. Other income was \$140,000 and \$217,000 for the nine months ended December 31, 2007 and 2006, respectively, with \$150,000 of the change resulting from a warrant benefit in the nine months ended December 31, 2006.

In May 2002, we conducted a public rights offering. In the rights offering, we issued to those shareholders who exercised their rights three shares of our common stock and a warrant, exercisable through July 2004, to purchase an additional share of our common stock. We registered with the SEC the issuance of the shares, the warrants and the shares underlying the warrants. In July 2004, we suspended the right to exercise the warrants shortly before their scheduled expiration date because we announced a planned restatement of our fiscal 2004 financial statements. In November 2004, we became current with our SEC filings. In April 2005, we chose to issue like-kind replacement warrants to the holders of the expired warrants. The terms for the replacement warrants required that we issue shares covered by a registration statement and maintain the effectiveness of the registration (by making timely SEC filings) for the warrant holders to receive registered shares upon exercise of the warrants. In April 2005, we recognized a liability and equity charge of \$1.4 million associated with the grant of these warrants, and subsequently recognized in other income (expense) the change in fair value of the warrants due to the change in the value of our common stock issuable upon exercise of these warrants. We determined the fair value of the warrants using the Black-Scholes option-pricing model. The period to exercise the warrants ended in March 2007. We recognized a net warrant benefit of \$150,000 during the nine months ended December 31, 2006.

We recognize exchange gains and losses primarily as a result of fluctuations in currency rates between the U.S. dollar (the functional reporting currency) and the Euro and British pound (currencies of our subsidiaries), as well as their effect on the dollar denominated short-term intercompany obligations between us and our foreign subsidiaries. We recognized foreign currency gains (losses) of \$(54,000) and \$34,000 for the nine months ended December 31, 2007 and 2006, respectively.

Income Tax Expense: During the nine months ended December 31, 2007 and 2006, our Dutch subsidiaries recorded income tax expense of \$140,600 and \$62,700, respectively. During the nine months ended December 31, 2007 and 2006, our U.S. organization recorded income tax expense of \$1,300 and \$0, respectively. We cannot use our U.S. net operating loss carry forwards to offset taxable income in foreign jurisdictions.

Non-GAAP Financial Measures. The following table reconciles our financial results calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non cash charges attributed to stock options under SFAS 123 (R), and depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used by other companies. We have described the reconciliations of each of our non-GAAP financial measures above to the most directly comparable GAAP financial measures.

Management uses our non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes because we believe such measures are one important indicator of the strength and the performance of our business because they provide a link to operating cash flow. We also believe that analysts and investors use such measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss of approximately \$466,000 and \$1.5 million for the three and six months ended December 31, 2007, respectively, declined from \$820,000 and \$3.3 million for the respective prior year periods. Included in the three and nine months ended December 31, 2007 is a \$214,000 charge attributed to rent and cost to exit the lease for our manufacturing facility in Eindhoven, The Netherlands and severance pay. We attribute the decline in non-GAAP operating loss primarily to the increase in sales and an improvement in gross margin rate, offset partially by an increase in cash operating expenses.



**Table of Contents**

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>December 31,</b>		<b>December 31,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
<b>Gross Profit</b>				
GAAP gross profit	\$ 2,939,359	\$ 1,406,092	\$ 7,664,323	\$ 3,922,700
% of sales	79%	65%	79%	69%
SFAS 123 (R) stock option charges	9,008		18,695	1,361
Depreciation expenses	13,277	12,330	41,882	36,358
Non-GAAP gross profit	2,961,644	1,418,422	7,724,900	3,960,419
<b>Operating Expenses</b>				
GAAP operating expenses	3,868,656	\$ 2,459,060	\$ 10,787,959	\$ 8,040,105
SFAS 123 (R) stock option charges	187,438	158,770	848,394	634,585
Depreciation expenses	43,842	37,015	122,001	108,367
Amortization expenses	209,862	25,210	632,865	78,323
Non-GAAP operating expenses	3,427,514	2,238,065	9,184,699	7,218,830
<b>Operating Loss</b>				
GAAP operating loss	(929,297)	(1,052,968)	(3,123,636)	(4,117,405)
SFAS 123 (R) stock option charges	196,446	158,770	867,089	635,946
Depreciation expenses	57,119	49,345	163,883	144,725
Amortization expenses	209,862	25,210	632,865	78,323
Non-GAAP operating loss	\$ (465,870)	\$ (819,643)	\$ (1,459,799)	\$ (3,258,411)

**Liquidity and Capital Resources***Cash Flows.*

As of December 31, 2007, our cash and cash equivalents balances totaled \$7.9 million and our short-term investments totaled \$2.4 million.

At December 31, 2007, we had working capital of approximately \$10.7 million. For the nine months ended December 31, 2007, we used \$1.6 million of cash in operating activities, compared to \$3.3 million of cash used in the same period a year ago. We attribute the decrease in cash used in operating activities primarily to the increase in sales and an improvement in gross profit rate, offset partially by increase in cash operating expenses.

*Sources of Liquidity.*

In August 2006, we entered into a securities purchase agreement with certain investors pursuant to which we sold approximately 1.4 million shares of our common stock for \$1.50 per share, together with warrants to purchase 695,000 shares of our common stock, for an aggregate purchase price of approximately \$2.1 million. After offset for our estimated costs of \$275,000, we received net proceeds of approximately \$1.8 million. The warrants are exercisable for five years (commencing 181 days after closing) at an exercise price of \$2.50 per share.

In December 2006, we conducted a follow-on public offering in which we sold 2,430,000 shares of our common stock at a price per share of \$2.00, resulting in net proceeds of approximately \$4.3 million.



**Table of Contents**

In November 2007, we conducted an additional follow-on public offering in which we sold 1,466,400 shares of our common stock at price of \$3.50 per share, for an aggregate purchase price of approximately \$5.1 million. The stock sale proceeds are offset by costs of approximately \$526,000, resulting in net proceeds of approximately \$4.6 million. For the nine months ended December 31, 2007, proceeds from exercise of warrants and options were \$785,000. In May 2007, we amended our business loan agreement with Venture Bank. The agreement, expiring in May 2008, provides for a credit line of up to \$1 million secured by our assets. We may borrow up to 50% (to a maximum of \$500,000) of the value of our eligible inventory on hand in the U.S. and 80% of our eligible U.S. accounts receivable value. To borrow any amount, we must maintain consolidated net equity of at least equal to \$3.5 million as well as maintain certain other financial covenants on a quarterly basis. The bank charges interest on the loan at a per annum rate of the greater of 7.5% or one percentage point over the prime rate (7.25% prime rate on December 31, 2007). In addition, Uroplasty BV, our subsidiary, entered into an agreement with Rabobank of The Netherlands for a 500,000 (approximately \$736,000) credit line. The bank charges interest on the loan at the rate of one percentage point over the Rabobank base interest rate (5.25% base rate on December 31, 2007), subject to a minimum interest rate of 3.5% per annum. At December 31, 2007, we had no borrowings under any of our credit lines.

We believe we have sufficient liquidity to meet our needs over the next twelve months. However, we may need to raise additional financing to support our operations and planned growth activities in the future as we have yet to achieve profitability and generate positive cash flows. To achieve profitability, we must generate substantially more revenue than we have this year or in prior years. Our ability to achieve significant revenue growth will depend, in large part, on our ability to achieve widespread market acceptance for our products and successfully expand our business in the U.S., which we cannot guarantee will happen. If we are unable to raise the needed funds, we may need to curtail our operations including product development, clinical studies and sales and marketing activities. This would adversely impact our future business and prospects. Ultimately, we will need to achieve profitability and generate positive cash flows from operations to fund our operations and grow our business.

For the balance of fiscal 2008, we expect to incur additional research and development expenses, including those in connection with clinical trials for the Urgent PC and FDA-required post-approval studies to obtain market feedback on safety and effectiveness of Macroplastique. We also expect that during the balance of fiscal 2008, we will continue to incur significant expenses as we fund our selling and marketing organization in the U.S. to market our products. Under a royalty agreement we pay royalties, in the aggregate, of three to five percent of net sales of Macroplastique, Bioplastique, and PTQ Implants subject to a monthly minimum of \$4,500. The royalties payable under this agreement will continue until the patent referenced in the agreement expires in 2010. Under a license agreement for the Macroplastique Implantation System, we pay a royalty of 10 British pounds for each unit sold during the life of the patent.

We have commitments, generally for periods less than twelve months, to purchase from various vendors finished goods and manufacturing components under issued purchase orders.

We have a pension plan covering seven employees in The Netherlands, reported as a defined benefit plan. We pay premiums to an insurance company to fund annuities for these employees. However, we are responsible for funding additional annuities based on continued service and future salary increases. We closed this defined benefit plan for new employees in April 2005. As of that date, the Dutch subsidiary established a defined contribution plan that now covers new employees. We also closed our UK subsidiary's defined benefit plan to further accrual for all employees effective December 31, 2004, and, effective March 2005, established a defined contribution plan that now covers new employees.

In January 2006, we entered into a long-term lease with Liberty Property Limited Partnership for an 18,258 square foot facility for our U.S. headquarters located at 5420 Feltri Road, Minnetonka, Minnesota. The lease effective date was May 1, 2006, has a term of 96 months, requires average annual minimum rent payments of approximately \$140,000 and requires payments for operating expenses we estimated at approximately \$89,000 over 12 months.

**Table of Contents**

Repayments of our contractual obligations as of December 31, 2007, consisting of royalties, notes payable (inclusive of interest), and operating leases, are summarized below:

	<b>Total</b>	<b>Payments Due by Period</b>			
		<b>Remainder of Fiscal 2008</b>	<b>Fiscal 2009 and 2010</b>	<b>Fiscal 2011 and 2012</b>	<b>Fiscal 2013 and thereafter</b>
Minimum royalty payments	\$ 153,000	\$ 13,500	\$ 108,000	\$ 31,500	\$
Purchase order commitments	433,058	253,723	179,335		
Notes payable, including interest	594,449	27,182	171,839	113,251	282,177
Operating lease commitments	968,694	51,473	336,048	284,557	296,616
<b>Total contractual obligations</b>	<b>\$ 2,149,201</b>	<b>\$ 345,878</b>	<b>\$ 795,222</b>	<b>\$ 429,308</b>	<b>\$ 578,793</b>

**ITEM 3. CONTROLS AND PROCEDURES.**

*Evaluation of Disclosure Controls Procedures.* Within the 90 days prior to the date of this report, our President and Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15b under the Securities Exchange Act of 1934. Based on this evaluation, these officers concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including such officers, to allow timely decisions regarding disclosure, and is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

*Internal Control Matters.* We also maintain a system of internal accounting controls designed to provide reasonable assurance that our books and records accurately reflect our transactions and that our policies and procedures are followed. There have been no changes in our internal control over financial reporting during the nine months ended December 31, 2007, or thereafter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Any control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of a control system inherently has limitations, and the benefits of controls must be weighed against their costs. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Therefore, no evaluation of a cost-effective system of controls can provide absolute assurance that all control issues and instances of fraud, if any, will be detected.



**Table of Contents**

**PART II. OTHER INFORMATION**

Except as indicated below, none of the items contained in PART II of Form 10-QSB are applicable to us for the nine months ended December 31, 2007.

**ITEM 6. EXHIBITS.**

(a) Exhibits

31.1 Certifications by the Chief Executive Officer and the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certifications by the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (this Exhibit is furnished pursuant to SEC rules, but is deemed not filed )

Page 25

---

**Table of Contents**

**SIGNATURES**

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UROPLASTY, INC.

Date: February 11, 2008

By: /s/ DAVID B. KAYSEN  
David B. Kaysen  
President and Chief Executive Officer

Date: February 11, 2008

By: /s/ MAHEDI A. JIWANI  
Mahedi A. Jiwani  
Chief Financial Officer

Page 26